

David S Siegel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4121420/publications.pdf>

Version: 2024-02-01

192
papers

11,291
citations

100601

38
h-index

35168

102
g-index

194
all docs

194
docs citations

194
times ranked

9424
citing authors

#	ARTICLE	IF	CITATIONS
1	Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. <i>Lancet Oncology</i> , The, 2022, 23, 65-76.	5.1	80
2	Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2â€‰MM-014 trial. <i>Leukemia and Lymphoma</i> , 2022, 63, 1407-1417.	0.6	8
3	Sustained Hematopoietic Engraftment Potential after Prolonged Storage of Cryopreserved Hematopoietic Stem Cells Used in Salvage Autologous Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 306.e1-306.e7.	0.6	2
4	Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United States. <i>Patient Preference and Adherence</i> , 2022, Volume 16, 573-585.	0.8	4
5	Overall survival of patients with tripleâ€‰class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in <sc>MAMMOTH</sc>. <i>American Journal of Hematology</i> , 2021, 96, E5-E8.	2.0	20
6	Overall survival with oral selinexor plus lowâ€‰dose dexamethasone versus realâ€‰world therapy in tripleâ€‰classâ€‰refractory multiple myeloma. <i>EJHaem</i> , 2021, 2, 48-55.	0.4	8
7	Efficacy and safety of weekly carfilzomib (70â€‰%mg/m ²), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies. <i>Leukemia and Lymphoma</i> , 2021, 62, 358-367.	0.6	13
8	Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2021, 384, 705-716.	13.9	1,129
9	Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma. <i>JCI Insight</i> , 2021, 6, .	2.3	29
10	Prevalence and Survival Impact of Self-Reported Symptom and Psychological Distress Among Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e284-e289.	0.2	9
11	Phase 1b trial of isatuximab, an antiâ€‰CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma. <i>Cancer</i> , 2021, 127, 1816-1826.	2.0	9
12	Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial. <i>EJHaem</i> , 2021, 2, 375-384.	0.4	2
13	Patientâ€‰reported outcomes following autologous stem cell transplant for patients with multiple myeloma. <i>EJHaem</i> , 2021, 2, 488-492.	0.4	4
14	KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 116.	2.8	44
15	Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2021, 62, 3002-3010.	0.6	6
16	Immune tolerance with combined allogeneic haploâ€‰identical haematopoietic stem cell transplant and renal transplant. <i>British Journal of Haematology</i> , 2021, 194, 779-783.	1.2	0
17	Selinexor for the treatment of patients with previously treated multiple myeloma. <i>Expert Review of Hematology</i> , 2021, 14, 697-706.	1.0	6
18	Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study. <i>Lancet Haematology</i> , the, 2021, 8, e794-e807.	2.2	15

#	ARTICLE	IF	CITATIONS
19	Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high-risk multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, E430-E433.	2.0	4
20	Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 651-651.	0.6	30
21	Inferior Outcomes of Patients with Quad and Penta-Refractory Multiple Myeloma (MM) Compared to Those of Patients Who Have Been Quad and Penta Exposed. <i>Blood</i> , 2021, 138, 4742-4742.	0.6	3
22	Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure. <i>British Journal of Haematology</i> , 2020, 188, 501-510.	1.2	36
23	Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. <i>Lancet, The</i> , 2020, 396, 186-197.	6.3	299
24	Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma. <i>Blood Advances</i> , 2020, 4, 5449-5459.	2.5	17
25	Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 5895-5902.	3.2	25
26	Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment. <i>Leukemia</i> , 2020, 34, 3286-3297.	3.3	64
27	Treatment of Smoldering Myeloma: Problems With Study Design as well as Biological and Clinical Implications. <i>Journal of Clinical Oncology</i> , 2020, 38, 1367-1368.	0.8	4
28	Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. <i>Leukemia</i> , 2020, 34, 2430-2440.	3.3	54
29	Once-weekly (70 mg/m ²) vs twice-weekly (56 mg/m ²) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION trials. <i>Cancer Medicine</i> , 2020, 9, 2989-2996.	1.3	16
30	Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study. <i>Blood</i> , 2020, 136, 37-38.	0.6	19
31	Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis. <i>Blood</i> , 2020, 136, 16-17.	0.6	18
32	Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study. <i>Blood</i> , 2020, 136, 26-27.	0.6	32
33	Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study. <i>Blood</i> , 2020, 136, 26-27.	0.6	13
34	First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 16-17.	0.6	28
35	Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma. <i>Leukemia</i> , 2019, 33, 2127-2143.	3.3	36
36	A phase I/II study of escalating doses of thalidomide in conjunction with bortezomib and high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 1881-1891.	1.3	2

#	ARTICLE	IF	CITATIONS
37	Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study. <i>American Journal of Hematology</i> , 2019, 94, 794-802.	2.0	10
38	Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019, 380, 1726-1737.	13.9	1,130
39	Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE-183. <i>British Journal of Haematology</i> , 2019, 186, e41-e44.	1.2	59
40	Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR. <i>Blood</i> , 2019, 133, 147-155.	0.6	33
41	Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study. <i>Blood</i> , 2019, 134, 1872-1872.	0.6	3
42	Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies. <i>Blood</i> , 2019, 134, 3125-3125.	0.6	10
43	Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy. <i>Blood</i> , 2019, 134, 927-927.	0.6	52
44	Elotuzumab As Post-Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Myeloma. <i>Blood</i> , 2019, 134, 3141-3141.	0.6	2
45	Sustained Hematopoietic Recovery after Salvage Autologous Stem Cell Transplants after Long Term Storage of Cryopreserved Hematopoietic Progenitor Stem Cells (HPSC). <i>Blood</i> , 2019, 134, 4475-4475.	0.6	0
46	Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. <i>British Journal of Haematology</i> , 2018, 180, 821-830.	1.2	32
47	Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series. <i>Leukemia and Lymphoma</i> , 2018, 59, 259-261.	0.6	10
48	Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2018, 36, 859-866.	0.8	140
49	Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2018, 36, 728-734.	0.8	221
50	The forgotten class of drugs for multiple myeloma: HDAC inhibitors. <i>Lancet Haematology</i> , 2018, 5, e604-e605.	2.2	6
51	Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia. <i>Blood</i> , 2018, 131, 855-863.	0.6	105
52	Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab. <i>Blood</i> , 2018, 132, 2012-2012.	0.6	3
53	Pomalidomide + Low-Dose Dexamethasone + Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure. <i>Blood</i> , 2018, 132, 3271-3271.	0.6	4
54	Carfilzomib-Lenalidomide-Dexamethasone Versus Bortezomib-Lenalidomide-Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Results from the Prospective, Longitudinal, Observational Compass Study. <i>Blood</i> , 2018, 132, 799-799.	0.6	7

#	ARTICLE	IF	CITATIONS
55	Patient Treatment Preferences for Relapsed/Refractory Multiple Myeloma: Are Patients Willing to Trade Off Efficacy for Tolerability?. <i>Blood</i> , 2018, 132, 614-614.	0.6	5
56	Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy. <i>Blood</i> , 2018, 132, 488-488.	0.6	61
57	Once Weekly Versus Twice Weekly Carfilzomib Dosing in Patients with Relapsed and Refractory Multiple Myeloma (A.R.R.O.W.): Efficacy and Safety Analyzed By Age Group. <i>Blood</i> , 2018, 132, 3277-3277.	0.6	2
58	Efficacy and Safety of Carfilzomib and Dexamethasone in Lenalidomide Exposed and Refractory Multiple Myeloma Patients: Combined Analysis of Carfilzomib Trials. <i>Blood</i> , 2018, 132, 1963-1963.	0.6	9
59	Safety and tolerability of pomalidomide-based regimens (pomalidomide+carfilzomib+dexamethasone with) a case series. <i>Hematological Oncology</i> , 2017, 35, 246-251.	0.8	5
60	Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2017, 58, 1872-1879.	0.6	50
61	Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. <i>British Journal of Haematology</i> , 2017, 177, 404-413.	1.2	58
62	Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. <i>European Journal of Haematology</i> , 2017, 99, 199-206.	1.1	21
63	Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma. <i>Leukemia</i> , 2017, 31, 2695-2701.	3.3	32
64	Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 555-562.	0.2	28
65	A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens. <i>British Journal of Haematology</i> , 2017, 176, 440-447.	1.2	11
66	Pembrolizumab (Pembro) plus lenalidomide (Len) and low-dose dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): Efficacy and biomarker analyses.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8015-8015.	0.8	13
67	Pomalidomide (POM) + low-dose dexamethasone (LoDEX) after lenalidomide (LEN)-based second-line (2L) treatment (Tx) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): Analysis of progression-free survival (PFS) by level of disease control.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8027-8027.	0.8	1
68	Real-world outcomes with panobinostat in patients with penta- and quad-refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2017, 35, e19522-e19522.	0.8	2
69	Elotuzumab for the treatment of multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2016, 9, 55.	6.9	36
70	Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 991-1002.	0.5	7
71	Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2016, 9, 51.	6.9	112
72	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. , 2016, 4, 90.		17

#	ARTICLE	IF	CITATIONS
73	Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. <i>Blood</i> , 2016, 127, 2955-2962.	0.6	686
74	Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3921-3930.	0.8	70
75	Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 558-562.	0.2	4
76	Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay. <i>British Journal of Haematology</i> , 2016, 173, 884-895.	1.2	29
77	Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up. <i>Blood Cancer Journal</i> , 2016, 6, e466-e466.	2.8	17
78	A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2165-2171.	2.0	15
79	Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices. <i>Expert Review of Hematology</i> , 2016, 9, 707-717.	1.0	37
80	Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. <i>Leukemia and Lymphoma</i> , 2016, 57, 2833-2838.	0.6	27
81	VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 329-334.e1.	0.2	26
82	Light Chain Proximal Tubulopathy: Clinical and Pathologic Characteristics in the Modern Treatment Era. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1555-1565.	3.0	130
83	Indatuximab Ravtansine (BT062) in Combination with Low-Dose Dexamethasone and Lenalidomide or Pomalidomide: Clinical Activity in Patients with Relapsed / Refractory Multiple Myeloma. <i>Blood</i> , 2016, 128, 4486-4486.	0.6	49
84	Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma. <i>British Journal of Haematology</i> , 2015, 171, 52-59.	1.2	32
85	Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 372, 142-152.	13.9	1,144
86	Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330). <i>Blood</i> , 2015, 126, 258-258.	0.6	13
87	Analysis of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with Vs without Moderate Renal Impairment. <i>Blood</i> , 2015, 126, 3031-3031.	0.6	3
88	A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005). <i>Blood</i> , 2015, 126, 3036-3036.	0.6	12
89	Phase 1 Study of CB-839, a First-in-Class, Glutaminase Inhibitor in Patients with Multiple Myeloma and Lymphoma. <i>Blood</i> , 2015, 126, 3059-3059.	0.6	17
90	Vorinostat in Combination with Lenalidomide (L) and Dexamethasone (d) in Multiple Myeloma Patients Refractory to Previous Lenalidomide-Containing Regimens: Results of a Phase IIb Trial. <i>Blood</i> , 2015, 126, 4264-4264.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023. <i>Blood</i> , 2015, 126, 505-505.	0.6	67
92	Identification of Initiating Trunk Mutations and Distinct Molecular Subtypes: An Interim Analysis of the Mmrf Compass Study. <i>Blood</i> , 2015, 126, 722-722.	0.6	4
93	Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391). <i>Blood</i> , 2015, 126, 731-731.	0.6	8
94	Ex Vivo Maintenance of Primary Human Multiple Myeloma Cells through the Optimization of the Osteoblastic Niche. <i>PLoS ONE</i> , 2015, 10, e0125995.	1.1	25
95	High Rate of Engraftment Syndrome in Elderly Patients with Multiple Myeloma Receiving Autologous Peripheral Blood Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 3175-3175.	0.6	0
96	Outcome with Lenalidomide Plus Dexamethasone Followed By Early Autologous Stem Cell Transplantation in the ECOG-ACRIN E4A03 Randomized Clinical Trial: Long-Term Follow-up. <i>Blood</i> , 2015, 126, 3174-3174.	0.6	0
97	Low-Risk Multiple Myeloma By SKY92+ISS Validated in the Multiple Myeloma Genomics Initiative Study. <i>Blood</i> , 2015, 126, 5322-5322.	0.6	0
98	Investigating Efficacy, Safety, and Biomarkers in a Phase 2 Trial of Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Following Second-Line Lenalidomide-Based Therapy (Tx) in Relapsed or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2015, 126, 1853-1853.	0.6	0
99	Costs per Month Free of Progression or Death of Targeted Therapies in the Treatment of Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2015, 126, 5369-5369.	0.6	0
100	Progression-Free Survival in Third-Line Treatment of Relapsed/Refractory Multiple Myeloma Among Patients with Who Have Received Prior Bortezomib and Immunomodulatory Drugs. <i>Blood</i> , 2015, 126, 3311-3311.	0.6	0
101	Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework. <i>American Health and Drug Benefits</i> , 2015, 8, 204-15.	0.5	39
102	Counterpoints: Do patients with multiple myeloma need maintenance treatment? No, maintenance treatment should not be used outside clinical trials. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 163, 167-9.	0.3	0
103	Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2014, 4, e182-e182.	2.8	43
104	The Graft-Versus-Myeloma Effect: Chronic Graft-Versus-Host Disease but Not Acute Graft-Versus-Host Disease Prolongs Survival in Patients with Multiple Myeloma Receiving Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1211-1216.	2.0	47
105	Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. <i>Blood</i> , 2014, 123, 1826-1832.	0.6	327
106	Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Waldenström Macroglobulinemia (WM). <i>Blood</i> , 2014, 124, 1715-1715.	0.6	28
107	Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study. <i>Blood</i> , 2014, 124, 34-34.	0.6	21
108	MM-008: A Phase 1 Trial Evaluating Pharmacokinetics and Tolerability of Pomalidomide + Low-Dose Dexamethasone in Patients with Relapsed or Refractory and Refractory Multiple Myeloma and Renal Impairment. <i>Blood</i> , 2014, 124, 4730-4730.	0.6	5

#	ARTICLE	IF	CITATIONS
109	Haploidentical Allogeneic Transplantation As Salvage in Relapsed Multiple Myeloma. <i>Blood</i> , 2014, 124, 5918-5918.	0.6	2
110	Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study. <i>Blood</i> , 2014, 124, 79-79.	0.6	15
111	Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of a Novel, First-in-Class Modulator of Eukaryotic Translation Initiation Factor 5A (eIF5A) in Patients (pts) with Relapsed or Refractory B-Cell Malignancies: Data from a Phase 1-2 Study. <i>Blood</i> , 2014, 124, 2121-2121.	0.6	0
112	Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. <i>Leukemia Research</i> , 2013, 37, 829-837.	0.4	48
113	Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE) Tj ETQq1 1 0.784314 rgBT /Ove	5.1	219
114	From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2013, 4, 354-365.	1.1	24
115	Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma. <i>Clinical Cancer Research</i> , 2013, 19, 2248-2256.	3.2	78
116	Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. <i>Blood</i> , 2013, 121, 1961-1967.	0.6	152
117	Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2013, 31, 3696-3703.	0.8	123
118	MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2013, 122, 1969-1969.	0.6	12
119	Clinical Profile Of Single-Agent Modified-Release Oprozomib Tablets In Patients (Pts) With Hematologic Malignancies: Updated Results From a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study. <i>Blood</i> , 2013, 122, 3184-3184.	0.6	15
120	Interim Analysis Of The Mmr Commpass Trial, a Longitudinal Study In Multiple Myeloma Relating Clinical Outcomes To Genomic and Immunophenotypic Profiles. <i>Blood</i> , 2013, 122, 532-532.	0.6	34
121	MM-008: A Phase 1 Trial Evaluating Pharmacokinetics and Tolerability Of Pomalidomide + Low-Dose Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment. <i>Blood</i> , 2013, 122, 5393-5393.	0.6	3
122	Preliminary Evidence Of Anti Tumor Activity Of Selinexor (KPT-330) In a Phase I Trial Of a First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Relapsed / Refractory Non Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2013, 122, 90-90.	0.6	23
123	Efficacy and Safety Of Pomalidomide Plus Low-Dose Dexamethasone In Advanced Multiple Myeloma: Results Of Randomized Phase 2 and 3 Trials (MM-002/MM-003). <i>Blood</i> , 2013, 122, 3185-3185.	0.6	0
124	Relationship Of Serum Free Light Chain Reduction To Best Overall Response In Phase 2 Single-Agent and Combination Studies Of Carfilzomib In Patients With Relapsed Or Relapsed and/Or Refractory Multiple Myeloma. <i>Blood</i> , 2013, 122, 1965-1965.	0.6	0
125	High Risk Multiple Myeloma Cases Are Identified In An MMRC Led Study By The SKY92 Gene Signature (MMprofler). <i>Blood</i> , 2013, 122, 1854-1854.	0.6	0
126	A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. <i>Blood</i> , 2012, 120, 2817-2825.	0.6	608

#	ARTICLE	IF	CITATIONS
127	Relapsed/Refractory Multiple Myeloma: Defining Refractory Disease and Identifying Strategies to Overcome Resistance. <i>Seminars in Hematology</i> , 2012, 49, S3-S15.	1.8	10
128	An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. <i>British Journal of Haematology</i> , 2012, 158, 739-748.	1.2	157
129	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. <i>Leukemia</i> , 2012, 26, 149-157.	3.3	664
130	Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2012, 53, 1820-1823.	0.6	109
131	MLN0128 (INK128), an Investigational Oral Dual TORC1/2 Inhibitor, in Patients (pts) with Relapsed or Refractory Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), or Waldenstrom Macroglobulinemia (WM): Preliminary Results From a Phase 1 Dose-Escalation Study. <i>Blood</i> , 2012, 120, 4038-4038.	0.6	18
132	MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2012, 120, 727-727.	0.6	9
133	Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. <i>Blood</i> , 2011, 117, 4691-4695.	0.6	849
134	A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2011, 52, 2308-2315.	0.6	25
135	Integrated Safety From Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (MM): An Updated Analysis. <i>Blood</i> , 2011, 118, 1876-1876.	0.6	13
136	Multivariate Modelling Reveals Evidence of a Dose-Response Relationship in Phase 2 Studies of Single-Agent Carfilzomib. <i>Blood</i> , 2011, 118, 1877-1877.	0.6	10
137	A Phase 1b/2 Study of Prolonged Infusion Carfilzomib in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma: Updated Efficacy and Tolerability From the Completed 20/56mg/m2 Expansion Cohort of PX-171-007. <i>Blood</i> , 2011, 118, 2930-2930.	0.6	15
138	The Speed of Response to Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma: An Exploratory Analysis of Results From 2 Multicenter Phase 2 Clinical Trials. <i>Blood</i> , 2011, 118, 3969-3969.	0.6	6
139	Salvage Therapy with Vorinostat, Lenalidomide, and Dexamethasone (ZRD) in Lenalidomide/Dexamethasone Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2011, 118, 3986-3986.	0.6	3
140	Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial. <i>Blood</i> , 2011, 118, 480-480.	0.6	21
141	Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results. <i>Blood</i> , 2011, 118, 634-634.	0.6	9
142	Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study. <i>Blood</i> , 2011, 118, 1875-1875.	0.6	2
143	The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development. <i>Blood</i> , 2011, 118, 1024-1024.	0.6	0
144	Differences in Patterns of Treatment and Outcome Among Patients with Relapsed Refractory Myeloma From United States, Europe and Asia. <i>Blood</i> , 2011, 118, 3989-3989.	0.6	0

#	ARTICLE	IF	CITATIONS
145	A Phase I Study of Vorinostat, Lenalidomide, and Dexamethasone In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Excellent Tolerability and Promising Activity In a Heavily Pretreated Population. <i>Blood</i> , 2010, 116, 1951-1951.	0.6	17
146	Vorinostat Combined with Bortezomib In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Update on the Vantage Study Program. <i>Blood</i> , 2010, 116, 1952-1952.	0.6	3
147	A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or In Combination with Low-Dose Dexamethasone In Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib. <i>Blood</i> , 2010, 116, 864-864.	0.6	4
148	Vorinostat in solid and hematologic malignancies. <i>Journal of Hematology and Oncology</i> , 2009, 2, 31.	6.9	152
149	The Combined Safety and Tolerability Profile of Vorinostat-Based Therapy for Solid or Hematologic Malignancies.. <i>Blood</i> , 2009, 114, 1710-1710.	0.6	1
150	Influence of Cytogenetics in Patients with Relapsed and Refractory Multiple Myeloma (MM) Treated with Carfilzomib (CFZ).. <i>Blood</i> , 2009, 114, 1827-1827.	0.6	2
151	Alkaline Phosphatase (ALP) Variation During Carfilzomib Treatment Is Associated to Best Response in Multiple Myeloma.. <i>Blood</i> , 2009, 114, 2865-2865.	0.6	3
152	Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study.. <i>Blood</i> , 2009, 114, 2878-2878.	0.6	18
153	A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib.. <i>Blood</i> , 2009, 114, 301-301.	0.6	9
154	Updated Results of Bortezomib-Naïve Patients in PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM).. <i>Blood</i> , 2009, 114, 302-302.	0.6	6
155	PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort.. <i>Blood</i> , 2009, 114, 303-303.	0.6	16
156	Combined Vorinostat, Lenalidomide and Dexamethasone Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase I Study.. <i>Blood</i> , 2009, 114, 305-305.	0.6	2
157	A Phase IB, Multi-Center, Open-Label Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma.. <i>Blood</i> , 2009, 114, 3852-3852.	0.6	11
158	Update On the Phase IIb, Open-Label Study of Vorinostat in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma.. <i>Blood</i> , 2009, 114, 3890-3890.	0.6	7
159	Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects.. <i>Blood</i> , 2009, 114, 430-430.	0.6	11
160	Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma: A phase I study. <i>Journal of Clinical Oncology</i> , 2009, 27, 8586-8586.	0.8	5
161	Phase 1/2 Study of Elotuzumab in Combination with Bortezomib in Patients with Multiple Myeloma with One to Three Prior Therapies: Interim Results.. <i>Blood</i> , 2009, 114, 3876-3876.	0.6	1
162	Combination Melphalan and Bortezomib Conditioning with Autologous Hematopoietic Stem Cell Support in Patients with Advanced Multiple Myeloma. A Phase I/II Study.. <i>Blood</i> , 2009, 114, 1214-1214.	0.6	1

#	ARTICLE	IF	CITATIONS
163	Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. <i>Leukemia and Lymphoma</i> , 2008, 49, 502-507.	0.6	185
164	Effect of Venous Thrombotic Events on Overall Survival in Multiple Myeloma: Analysis of Thrombotic Events Occurring in E4A03A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma, a Trial Coordinated by the Eastern Cooperative Oncology Group (ECOG).. <i>Blood</i> , 2008, 112, 1740-1740.	0.6	5
165	A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma. <i>Blood</i> , 2008, 112, 2774-2774.	0.6	19
166	A Phase I Trial of SNS-032, a Potent and Specific CDK 2, 7 and 9 Inhibitor, in Chronic Lymphocytic Leukemia and Multiple Myeloma. <i>Blood</i> , 2008, 112, 3178-3178.	0.6	4
167	First Trial of Humanized Anti-CD74 Monoclonal Antibody (MAb), Milatuzumab, in Multiple Myeloma. <i>Blood</i> , 2008, 112, 3697-3697.	0.6	3
168	Longer Duration of Treatment and Maintenance of Best Response with Lenalidomide and Dexamethasone Prolongs Overall Survival in Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2008, 112, 3702-3702.	0.6	6
169	A Phase I Study of Vorinostat in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2008, 112, 3705-3705.	0.6	8
170	Response Duration with Initial Therapy Is a Major Predictor of Overall Survival in Multiple Myeloma: Analysis from Multiple Phase III ECOG Clinical Trials. <i>Blood</i> , 2008, 112, 5129-5129.	0.6	3
171	A Phase I Trial of Fluphenazine HCl (Fz), a Serotonin Antagonist, in Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2008, 112, 5188-5188.	0.6	2
172	Initial Results of PX-171-003, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed and Refractory Multiple Myeloma (MM). <i>Blood</i> , 2008, 112, 864-864.	0.6	14
173	Initial Results of PX-171-004, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM). <i>Blood</i> , 2008, 112, 865-865.	0.6	12
174	Vorinostat Plus Bortezomib for the Treatment of Relapsed/Refractory Multiple Myeloma: Early Clinical Experience. <i>Blood</i> , 2008, 112, 871-871.	0.6	23
175	Guillain-Barre Syndrome Complicating Multiple Myeloma. <i>Blood</i> , 2008, 112, 5135-5135.	0.6	1
176	Outcome of Patients with Myeloproliferative Disorders Treated with Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2008, 112, 2797-2797.	0.6	0
177	Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma.. <i>Blood</i> , 2007, 110, 1179-1179.	0.6	10
178	A Phase I Trial of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) in Combination with Bortezomib in Patients with Relapsed/Refractory Mantle Cell Lymphoma.. <i>Blood</i> , 2007, 110, 2569-2569.	0.6	18
179	Updated Survival Analyses after Prolonged Follow-Up of the Phase 2, Multicenter CREST Study of Bortezomib in Relapsed or Refractory Multiple Myeloma.. <i>Blood</i> , 2007, 110, 2717-2717.	0.6	2
180	A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group.. <i>Blood</i> , 2007, 110, 74-74.	0.6	57

#	ARTICLE	IF	CITATIONS
181	Cryopreservation of Peripheral Blood Stem Cells (PBSC) with Hydroxyethylstarch (HES) and Dimethylsulfoxide (DMSO) Results in Faster Granulocyte Recovery Than Using Dimethylsulfoxide Alone.. Blood, 2007, 110, 3287-3287.	0.6	0
182	Genomic-Wide Profiling of Gene Expression and DNA Copy Number Alterations in Multiple Myeloma.. Blood, 2007, 110, 396-396.	0.6	0
183	A New Mouse Model of Multiple Myeloma: Engraftment of Primary Human Multiple Myeloma in SCID/Beige Mice.. Blood, 2007, 110, 3532-3532.	0.6	14
184	DCEP (Dexamethasone, Cyclophosphamide, Etoposide, Cisplatin) Followed by High-Dose G-CSF Is a Highly Efficient and Safe Regimen for Stem Cell Mobilization for Multiple Myeloma.. Blood, 2007, 110, 3284-3284.	0.6	0
185	Lenalidomide in Combination with Dexamethasone Was More Effective Than Dexamethasone in Patients Who Have Received Prior Thalidomide for Relapsed or Refractory Multiple Myeloma.. Blood, 2006, 108, 3553-3553.	0.6	7
186	Phase II Trial of SCIO-469 as Monotherapy (M) or in Combination with Bortezomib (MB) in Relapsed Refractory Multiple Myeloma (MM).. Blood, 2006, 108, 3580-3580.	0.6	21
187	5-Azacytidine Therapy in Elderly Patients with Acute Myelogenous Leukemia Yields Similar Survival Compared to 3+7 Induction Chemotherapy with Less Transfusional Support, Bacteremias, and Hospital Days.. Blood, 2006, 108, 4569-4569.	0.6	0
188	Long-Term Survival of Patients with Myelofibrosis Treated with Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2006, 108, 2704-2704.	0.6	0
189	Phase I Clinical Trial of IPI-504, a Novel, Water-Soluble Hsp90 Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM).. Blood, 2005, 106, 2560-2560.	0.6	4
190	Risk Adapted Dose Intensive DICEP Salvage Chemotherapy Prior to Autologous Stem Cell Transplantation Yields Successful Outcomes in Chemotherapy Refractory Lymphoma.. Blood, 2004, 104, 898-898.	0.6	1
191	Autologous Peripheral Blood Stem Cell Transplant for Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma Results in Inferior Long Term Survival when Compared to Relapsed or Refractory B-Cell Non-Hodgkin's Lymphomas.. Blood, 2004, 104, 5241-5241.	0.6	0
192	A Myeloablative Conditioning Regimen Is Required to Produce Durable Engraftment and Immune Reconstitution in Related and Unrelated Multi-Antigen HLA Mismatched Pan-T-Cell Depleted Limited T-Cell Add-Back Transplants.. Blood, 2004, 104, 5185-5185.	0.6	0